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Kidney International (2009) 76 (Suppl 113), S1–S2; doi:10.1038/ki.2009.188

Clinical practice guidelines serve many purposes. First and
foremost, guidelines help clinicians and other caregivers deal
with the exponential growth in medical literature. It is
impossible for most busy practitioners to read, understand,
and apply a rapidly changing knowledge base to daily clinical
practice. Guidelines can help fill this important need.
Guidelines can also help to expose gaps in our knowledge,
and thereby suggest areas where additional research is
needed. Only when evidence is sufficiently strong to conclude
that additional research is not needed should guidelines be
used to mandate specific medical practices with, for example,
clinical performance measures.
Methods for developing and implementing clinical
practice guidelines are still relatively new and many questions
remain unanswered. How should it be determined when a
clinical practice guideline is needed? Who should make that
determination? Who should develop guidelines? Should
specialists develop guidelines for their practice, or should
unbiased, independent clinicians and scientists develop
guidelines for them? Is it possible to avoid conflicts of
interest when most experts in a field conduct research that
has been funded by industry (often because no other funding
is available)? Should guidelines offer guidance when strong
evidence is lacking, should they point out what decisions
must be made in the absence of evidence or guidance, or
should they just ignore these questions altogether, that is,
make no statements or recommendations?
Professional societies throughout the world have decided
that there is a need for developing clinical practice guidelines
for patients with chronic kidney disease (CKD). Along with
this perceived need has come the realization that developing
high-quality guidelines requires substantial resources and
expertise. An uncoordinated and parallel or repetitive
development of guidelines on the same topics reflects a
waste of resources. In addition, there is a growing awareness
that CKD is an international problem. Therefore, Kidney
Disease: Improving Global Outcomes (KDIGO) was established in 2003 as an independent, nonprofit foundation,
governed by an international board of directors, with its
stated mission to ‘improve the care and outcomes of kidney
disease patients worldwide through promoting coordination,
collaboration, and integration of initiatives to develop and
implement clinical practice guidelines.’
To date, KDIGO guideline initiatives have originated in
discussions among the KDIGO Executive Committee members and the KDIGO Board of Directors. In some instances,
topic areas have been vetted at KDIGO ‘Controversies
Conferences.’ If there is then a consensus that guideline
development should go forward, two Work Group chairs are
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appointed, and with the help of these chairs, other Work
Group members are selected. Efforts are made to include a
broad and diverse expertise in the Work Group, and to have
international representation. Work Groups then meet and
work with a trained, professional evidence review team to
develop evidence-based guidelines. These guidelines are
reviewed by the KDIGO Board of Directors, and a revision
is then sent out for public comment. Only then is a final,
revised version developed and published.
The mineral and bone disorder of CKD (CKD–MBD) has
been an area of intense interest and controversy. In 2005,
KDIGO sponsored a controversies conference ‘Definition,
Evaluation and Classification of Renal Osteodystrophy.’ The
results of this conference were summarized in a position
statement that was published in 2006. The consensus
of the attendees at this conference was that a new set
of international guideline on CKD–MBD was indeed
warranted.
Therefore, KDIGO invited Sharon Moe, MD, and Tilman
Drüeke, MD, to co-chair a Work Group to develop a
CKD–MBD guideline. The Work Group was supported by the
Evidence Review Team at the Tufts Center for Kidney Disease
Guideline Development and Implementation at Tufts Medical Center, Boston, MA, with Katrin Uhlig, MD, MS, as the
Evidence Review Team’s Project Director. The Work Group
met on five separate occasions over a period of 2 years,
reviewing evidence and drafting guideline recommendations.
The KDIGO Board reviewed a preliminary draft, and
ultimately the final document. Importantly, the guideline
was also subjected to public review and comment.
During the development of the CKD–MBD guideline,
KDIGO continued to develop a system for rating the strength
of recommendations and the overall quality of evidence
supporting those recommendations. A task force had been
formed that ultimately made recommendations to the
KDIGO Board. After extensive discussion and debate, the
KDIGO Board of Directors in 2008 unanimously approved a
modification of the Grading of Recommendations Assessment, Development, and Evaluation system. The system that
was adopted allows provision of guidance even if the evidence
base is weak, but makes the quality of the available evidence
transparent and explicit. It is described in detail in the
present CKD–MBD guideline (Chapter 2).
The strength of each recommendation is rated 1 or 2, with
1 being a ‘We recommend y’ statement implying that most
patients should receive the course of action, and 2 being a
‘We suggest y’ statement implying that different choices will
be appropriate for different patients with the suggested
course of action being a reasonable choice. In addition, each
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statement is assigned an overall grade for the quality of
evidence, A (high), B (moderate), C (low), or D (very low).
The grade of each recommendation depends on the quality of
the evidence, and also on additional considerations.
A key issue is whether to include guideline statements on
topics that cannot be subjected to a systematic evidence
review. KDIGO has decided to meet this need by including
some statements that are not graded. Typically, ungraded
statements provide guidance that is based on common
sense, for example, reminders of the obvious and/or
recommendations that are not sufficiently specific enough
to allow the application of evidence. Examples include the
frequency of laboratory testing and the provision of routine
medical care.
The CKD–MBD guideline encompasses many aspects of
care for which there is little or no evidence to inform
recommendations. Indeed, there are only three recommendations in the CKD–MBD guideline for which the overall
quality of evidence was graded ‘A,’ whereas 12 were graded
‘B,’ 23 were graded ‘C,’ and 11 were graded ‘D.’ Although
there are reasons other than quality of evidence to make a
grade 1 or 2 recommendation, in general, there is a
correlation between the quality of overall evidence and the
strength of the recommendation. Thus, there are 10
recommendations graded ‘1’ and 39 graded ‘2.’ There were
two recommendations graded ‘1A,’ five were ‘1B,’ three were
‘1C,’ and none were ‘1D.’ There was one graded ‘2A,’ seven
were ‘2B,’ 20 were ‘2C,’ and 11 were ‘2D.’ There were 12
statements that were not graded.
The grades should be taken seriously. The lack of
recommendations that are graded ‘1A’ suggests that there
are few opportunities for developing clinical performance
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measures from this guideline. The preponderance of ‘2’
recommendations suggests that patient preferences and
other circumstances should be strongly considered when
implementing most recommendations. The lack of ‘A’ and ‘B’
grades of overall quality of evidence is a result of the lack of
patient-centered outcomes as end points in the majority of
trials in this field, and thus suggests strongly that additional
research is needed in CKD–MBD. Indeed, the extensive
review that led to this guideline often exposed significant
gaps in our knowledge. The Work Group made a number of
specific recommendations for future research needs. This will
hopefully be of interest to future investigators and funding
agencies.
All of us working with KDIGO hope that the guidelines
developed by KDIGO will in some small way help to fulfill its
mission to improve the care and outcomes of patients with
kidney disease. We understand that these guidelines are far
from perfect, but we are confident that they are an important
step in the right direction. A tremendous amount of work has
gone into the development of the KDIGO CKD–MBD
guideline. We sincerely thank Sharon Moe, MD, and Tilman
Drüeke, MD, the Work Group chairs, for the tremendous
amount of time and effort that they put into this challenging,
but important, guideline project. They did an outstanding
job. We also thank the Work Group members, the Evidence
Review Team, and the KDIGO staff for their tireless efforts.
Finally, we owe a special debt of gratitude to the founding
KDIGO Co-Chairs, Norbert Lameire, MD, and especially
Garabed Eknoyan, MD, for making all of this possible.
Kai-Uwe Eckardt, MD
Co-Chair, KDIGO

Bertram L Kasiske, MD
Co-Chair, KDIGO
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